<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329885</url>
  </required_header>
  <id_info>
    <org_study_id>IM024-005</org_study_id>
    <secondary_id>2017-003408-38</secondary_id>
    <nct_id>NCT03329885</nct_id>
  </id_info>
  <brief_title>A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis</brief_title>
  <official_title>A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth
      in healthy patients and patients with average to very serious Psoriasis (a condition
      characterized by itchy, dry skin with a scaly rash).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Adverse change in the risk/benefit
  </why_stopped>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Actual">June 26, 2018</completion_date>
  <primary_completion_date type="Actual">June 26, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Experienced the Following: Serious Adverse Events (SAEs), Death or an Adverse Event (AE) Leading to Study Discontinuation</measure>
    <time_frame>AEs: Day 1 to Day 11 (Part A), Day 1 to Day 24 (Part B); SAEs: Day -21 to within 30 days of discontinuation of dosing (Part A), Day -21 to within 30 days of discontinuation of dosing (Part B)</time_frame>
    <description>An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with the treatment. A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose results in death or is life-threatening or requires inpatient hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Changes in Vital Signs</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9 and 11; Part B: Days 1, 2-13, 15, 16, 18, 20, 24</time_frame>
    <description>Vital signs (Systolic and diastolic blood pressure and pulse) were recorded after the participant had been resting for at least 5 minutes in the supine position.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Changes in Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Part A: Days 1, 2, 3,5, 7 and 11; Part B: Days 1, 2, 4, 6, 8, 10, and 12,24</time_frame>
    <description>The following ECG parameters were recorded: heart rate, PR-interval, QRS-duration, QT-interval, QTcinterval, (Fridericia's) and the interpretation of the ECG profile by the Investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Parameters</measure>
    <time_frame>Part A: Days 2, 4, 7 and 11; Part B: Days 3, 7, 10, 14, 16, 24</time_frame>
    <description>Hematology: Hemoglobin, Hematocrit, Total leukocyte count, including differential Platelet count, Red blood cell count, Reticulocyte count; Chemistry:
Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Total bilirubin, Direct bilirubin, Alkaline phosphatase, Lactate dehydrogenase , (LDH), Creatinine, Urea, Uric acid, Fasting glucose, High sensitivity C-reactive protein (hs-CRP), Total protein, Albumin Sodium, Potassium, Chloride, Calcium Inorganic phosphate, Magnesium, Creatine kinase, Creatinine clearance (CLcr)- screening only, Cholesterol Triglycerides, High-density lipoprotein (HDL), Low-density lipoprotein (LDL), Urinalysis: Protein, Glucose, Blood Leukocyte esterase, Specific gravity, pH,Microscopic examination of the sediment if blood, protein or leukocytes esterase are positive on the dipstick; Other Analyses: Urine test for alcohol, Urine test for drugs of abuse, Pregnancy test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 1 and 14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 1 and 14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration [AUC(0-t)]</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 1 and 14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] (Part A)</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life, Calculated as 0.693/Kel [t(1/2)]</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent (Oral) Clearance (CL/F) Calculated as Dose/[AUC(0-inf)] for Single Dose</measure>
    <time_frame>Part A: Day 1, Part B: Day 14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution at Terminal Phase [V(z)/F]</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Urinary Excretion (of the Unchanged Drug) [Ae(t)]</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7 ; Part B : Day 14</time_frame>
    <description>Summary of BMS-986251 Excretion Parameters in Urine. PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount Excreted Unchanged in Urine (% of Dose) [Fe(Urine)%]</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7 ; Part B : Day 14</time_frame>
    <description>Summary of BMS-986251 Excretion Parameters in Urine. PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance [CL(R)]</measure>
    <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7 ; Part B : Day 14</time_frame>
    <description>Summary of BMS-986251 Excretion Parameters in Urine. PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve Over 24 Hours (One Dosing Interval) [AUC(0-24)] (Part B)</measure>
    <time_frame>Part B : Days 1 and Day 14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of AUC(0-24) Following Last Dose to AUC(0-24) Following First Dose [AR[AUC(0-24)]] (Part B)</measure>
    <time_frame>Part B : Day 14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax Following Last Dose to Cmax Following First Dose [AR(Cmax)] (Part B)</measure>
    <time_frame>Part B : Day 14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-dose Plasma Concentration (Cpre) (Part B)</measure>
    <time_frame>Part B : Days 2-14</time_frame>
    <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inhibition at Time t [I(t)] (Part B)</measure>
    <time_frame>Part B : Days 16, 20, and 24</time_frame>
    <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Inhibition [I(Max)]</measure>
    <time_frame>Part A: Days 1, 2, 3, 5, 7, 11 ; Part B : Day 1, 2, 16, 20, 24</time_frame>
    <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Inhibition [t(Imax)]</measure>
    <time_frame>Part A: Days 1, 2, 3, 5, 7, 11 ; Part B : Day 1, 2, 16, 20, 24</time_frame>
    <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Inhibition Above 50% [t(I&gt;50%)]</measure>
    <time_frame>Part A: Days 1, 2, 3, 5, 7, 11 ; Part B : Day 1, 2, 16, 20, 24</time_frame>
    <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Inhibition Above 90% [t(I&gt;90%)]</measure>
    <time_frame>Part A: Days 1, 2, 3, 5, 7, 11 ; Part B : Day 1, 2, 16, 20, 24</time_frame>
    <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Inhibition [I(Pre)] (Part B)</measure>
    <time_frame>Part B : Days 2, 4, 7, and 14</time_frame>
    <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriasis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Part A Single Ascending Dose (SAD) in Healthy Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy patient will receive single escalating oral doses of BMS-986251 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Multiple Ascending Dose (MAD) in Healthy Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Multiple Dosing in Psoriasis Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986251</intervention_name>
    <description>Escalating oral dose</description>
    <arm_group_label>Part A Single Ascending Dose (SAD) in Healthy Patients</arm_group_label>
    <arm_group_label>Part B Multiple Ascending Dose (MAD) in Healthy Patients</arm_group_label>
    <arm_group_label>Part C Multiple Dosing in Psoriasis Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Escalating oral dose</description>
    <arm_group_label>Part A Single Ascending Dose (SAD) in Healthy Patients</arm_group_label>
    <arm_group_label>Part B Multiple Ascending Dose (MAD) in Healthy Patients</arm_group_label>
    <arm_group_label>Part C Multiple Dosing in Psoriasis Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria (Healthy Patients):

          -  Males and females, ages 18 to 55 years, inclusive, at screening

          -  Healthy subjects, as determined by no clinically significant deviations from normal in
             medical history, physical examination, 12-lead ECGs, vital signs, and clinical
             laboratory results

          -  Body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive, at screening

          -  Body weight between 55 kg and 105 kg, inclusive, at screening

          -  Women must not be breastfeeding

        Exclusion Criteria (Healthy Patients):

          -  Previous participation in the current study

          -  Participation in a drug study or exposure to any investigational drug or placebo
             within 2 months prior to (the first) drug administration in the current study

          -  Employees of PRA or the Sponsor and their relatives

          -  Any significant acute or chronic medical condition that presents a potential risk to
             the subject and/or that may compromise the objectives of the study, including active,
             or history of, liver disease, or intestinal disorder including irritable bowel
             syndrome

          -  Current or recent (within 3 months of study treatment administration) gastrointestinal
             disease that could affect pharmacokinetics; history of cholecystectomy is not allowed

        Inclusion Criteria (Psoriasis Patients):

          -  Males and females, ages 18 to 70 years, inclusive, at screening

          -  BMI of 18.0 to 35.0 kg/m2, inclusive, at screening

          -  Body weight between 55 kg and 120 kg, inclusive, at screening

          -  Diagnosed with stable chronic plaque psoriasis, for at least 6 months prior to
             screening and be candidates for either photo-therapy or systemic treatment

          -  Moderate-to-severe intensity of psoriasis as defined by:

               1. Affected body surface area (BSA) of ≥10%

               2. Psoriasis Area and Severity Index (PASI) ≥12

               3. Physician Global Assessment (PGA; 6-point scale) ≥3

        Exclusion Criteria (Psoriasis Patients):

          -  Previous participation in the current study

          -  Participation in a drug study or exposure to any investigational drug or placebo
             within 2 months prior to (the first) drug administration in the current study

          -  Employees of PRA or the Sponsor and their relatives

          -  Any significant acute or chronic medical condition that presents a potential risk to
             the subject and/or that may compromise the objectives of the study, including active,
             or history of, liver disease, or intestinal disorder including irritable bowel
             syndrome

          -  Current or recent (within 3 months of study treatment administration) gastrointestinal
             disease that could affect pharmacokinetics; history of cholecystectomy is not allowed

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>June 26, 2019</results_first_submitted>
  <results_first_submitted_qc>September 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 21, 2019</results_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03329885/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03329885/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>96 participants were enrolled (screened) of whom 36 were screen failures, 22 were approved but not dosed and 38 were randomized in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Placebo</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="P2">
          <title>Part A: BMS-986251 2 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="P3">
          <title>Part A: BMS-986251 6 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="P4">
          <title>Part A: BMS-986251 15 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="P5">
          <title>Part A: BMS-986251 30 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="P6">
          <title>Part A : BMS-986251 60 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="P7">
          <title>Part B: Placebo</title>
          <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="P8">
          <title>Part B: 3 mg QD (Once Daily)</title>
          <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="P9">
          <title>Part C: Multiple Dosing in Psoriasis Patients</title>
          <description>Psoriasis patients to receive daily escalating oral doses of BMS-986251 or placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0">Due to early termination of study, Part C was cancelled and no patients were dosed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor discontinued the study early</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All demographic characteristics for Part A are summarized. Due to early termination of the study, only 1 participant was enrolled in the placebo group and 1 participant in the BMS-986251 group in Part B. Part B demographics data is not reported for privacy reasons.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: Placebo</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="B2">
          <title>Part A: BMS-986251 2 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="B3">
          <title>Part A: BMS-986251 6 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="B4">
          <title>Part A: BMS-986251 15 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="B5">
          <title>Part A: BMS-986251 30 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="B6">
          <title>Part A : BMS-986251 60 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="10.46"/>
                    <measurement group_id="B2" value="34.5" spread="7.96"/>
                    <measurement group_id="B3" value="32.3" spread="11.64"/>
                    <measurement group_id="B4" value="37.2" spread="12.26"/>
                    <measurement group_id="B5" value="33.8" spread="12.52"/>
                    <measurement group_id="B6" value="29.0" spread="6.56"/>
                    <measurement group_id="B7" value="33.1" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Experienced the Following: Serious Adverse Events (SAEs), Death or an Adverse Event (AE) Leading to Study Discontinuation</title>
        <description>An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with the treatment. A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose results in death or is life-threatening or requires inpatient hospitalization</description>
        <time_frame>AEs: Day 1 to Day 11 (Part A), Day 1 to Day 24 (Part B); SAEs: Day -21 to within 30 days of discontinuation of dosing (Part A), Day -21 to within 30 days of discontinuation of dosing (Part B)</time_frame>
        <population>All participants who had received at least one dose of BMS-986251 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experienced the Following: Serious Adverse Events (SAEs), Death or an Adverse Event (AE) Leading to Study Discontinuation</title>
          <description>An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with the treatment. A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose results in death or is life-threatening or requires inpatient hospitalization</description>
          <population>All participants who had received at least one dose of BMS-986251 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of participants that experienced SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of participants that died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of participants with AE leading to study discon.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Significant Changes in Vital Signs</title>
        <description>Vital signs (Systolic and diastolic blood pressure and pulse) were recorded after the participant had been resting for at least 5 minutes in the supine position.</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9 and 11; Part B: Days 1, 2-13, 15, 16, 18, 20, 24</time_frame>
        <population>All participants who had received at least one dose of BMS-986251 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Changes in Vital Signs</title>
          <description>Vital signs (Systolic and diastolic blood pressure and pulse) were recorded after the participant had been resting for at least 5 minutes in the supine position.</description>
          <population>All participants who had received at least one dose of BMS-986251 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Significant Changes in Electrocardiogram (ECG) Parameters</title>
        <description>The following ECG parameters were recorded: heart rate, PR-interval, QRS-duration, QT-interval, QTcinterval, (Fridericia's) and the interpretation of the ECG profile by the Investigator</description>
        <time_frame>Part A: Days 1, 2, 3,5, 7 and 11; Part B: Days 1, 2, 4, 6, 8, 10, and 12,24</time_frame>
        <population>All participants who had received at least one dose of BMS-986251 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Changes in Electrocardiogram (ECG) Parameters</title>
          <description>The following ECG parameters were recorded: heart rate, PR-interval, QRS-duration, QT-interval, QTcinterval, (Fridericia's) and the interpretation of the ECG profile by the Investigator</description>
          <population>All participants who had received at least one dose of BMS-986251 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Parameters</title>
        <description>Hematology: Hemoglobin, Hematocrit, Total leukocyte count, including differential Platelet count, Red blood cell count, Reticulocyte count; Chemistry:
Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Total bilirubin, Direct bilirubin, Alkaline phosphatase, Lactate dehydrogenase , (LDH), Creatinine, Urea, Uric acid, Fasting glucose, High sensitivity C-reactive protein (hs-CRP), Total protein, Albumin Sodium, Potassium, Chloride, Calcium Inorganic phosphate, Magnesium, Creatine kinase, Creatinine clearance (CLcr)- screening only, Cholesterol Triglycerides, High-density lipoprotein (HDL), Low-density lipoprotein (LDL), Urinalysis: Protein, Glucose, Blood Leukocyte esterase, Specific gravity, pH,Microscopic examination of the sediment if blood, protein or leukocytes esterase are positive on the dipstick; Other Analyses: Urine test for alcohol, Urine test for drugs of abuse, Pregnancy test</description>
        <time_frame>Part A: Days 2, 4, 7 and 11; Part B: Days 3, 7, 10, 14, 16, 24</time_frame>
        <population>All participants who had received at least one dose of BMS-986251 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Parameters</title>
          <description>Hematology: Hemoglobin, Hematocrit, Total leukocyte count, including differential Platelet count, Red blood cell count, Reticulocyte count; Chemistry:
Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Total bilirubin, Direct bilirubin, Alkaline phosphatase, Lactate dehydrogenase , (LDH), Creatinine, Urea, Uric acid, Fasting glucose, High sensitivity C-reactive protein (hs-CRP), Total protein, Albumin Sodium, Potassium, Chloride, Calcium Inorganic phosphate, Magnesium, Creatine kinase, Creatinine clearance (CLcr)- screening only, Cholesterol Triglycerides, High-density lipoprotein (HDL), Low-density lipoprotein (LDL), Urinalysis: Protein, Glucose, Blood Leukocyte esterase, Specific gravity, pH,Microscopic examination of the sediment if blood, protein or leukocytes esterase are positive on the dipstick; Other Analyses: Urine test for alcohol, Urine test for drugs of abuse, Pregnancy test</description>
          <population>All participants who had received at least one dose of BMS-986251 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 1 and 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="74.3" spread="5.88"/>
                    <measurement group_id="O3" value="206" spread="55.8"/>
                    <measurement group_id="O4" value="659" spread="207"/>
                    <measurement group_id="O5" value="1131" spread="278"/>
                    <measurement group_id="O6" value="2147" spread="175"/>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Observed Plasma Concentration (Tmax)</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 1 and 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Plasma Concentration (Tmax)</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.50" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.27" lower_limit="1.02" upper_limit="4.02"/>
                    <measurement group_id="O4" value="1.53" lower_limit="1.02" upper_limit="8.00"/>
                    <measurement group_id="O5" value="2.53" lower_limit="2.02" upper_limit="4.02"/>
                    <measurement group_id="O6" value="1.05" lower_limit="1.02" upper_limit="1.07"/>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration [AUC(0-t)]</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 1 and 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration [AUC(0-t)]</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5530" spread="954"/>
                    <measurement group_id="O3" value="14737" spread="3339"/>
                    <measurement group_id="O4" value="36318" spread="9554"/>
                    <measurement group_id="O5" value="71172" spread="13328"/>
                    <measurement group_id="O6" value="126198" spread="21811"/>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] (Part A)</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] (Part A)</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6052" spread="1221"/>
                    <measurement group_id="O3" value="15815" spread="3926"/>
                    <measurement group_id="O4" value="38080" spread="10827"/>
                    <measurement group_id="O5" value="75335" spread="14726"/>
                    <measurement group_id="O6" value="130873" spread="24294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life, Calculated as 0.693/Kel [t(1/2)]</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life, Calculated as 0.693/Kel [t(1/2)]</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="70.9" spread="16.5"/>
                    <measurement group_id="O3" value="62.6" spread="15.0"/>
                    <measurement group_id="O4" value="52.2" spread="9.02"/>
                    <measurement group_id="O5" value="54.6" spread="13.6"/>
                    <measurement group_id="O6" value="48.2" spread="7.02"/>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent (Oral) Clearance (CL/F) Calculated as Dose/[AUC(0-inf)] for Single Dose</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Day 1, Part B: Day 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent (Oral) Clearance (CL/F) Calculated as Dose/[AUC(0-inf)] for Single Dose</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.343" spread="0.076"/>
                    <measurement group_id="O3" value="0.400" spread="0.100"/>
                    <measurement group_id="O4" value="0.419" spread="0.109"/>
                    <measurement group_id="O5" value="0.411" spread="0.078"/>
                    <measurement group_id="O6" value="0.469" spread="0.083"/>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution at Terminal Phase [V(z)/F]</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7, 9, 11; Part B : Day 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution at Terminal Phase [V(z)/F]</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="34.1" spread="6.39"/>
                    <measurement group_id="O3" value="35.3" spread="8.52"/>
                    <measurement group_id="O4" value="30.6" spread="5.54"/>
                    <measurement group_id="O5" value="32.3" spread="9.44"/>
                    <measurement group_id="O6" value="32.1" spread="3.98"/>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Urinary Excretion (of the Unchanged Drug) [Ae(t)]</title>
        <description>Summary of BMS-986251 Excretion Parameters in Urine. PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7 ; Part B : Day 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Urinary Excretion (of the Unchanged Drug) [Ae(t)]</title>
          <description>Summary of BMS-986251 Excretion Parameters in Urine. PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0.002" spread="0.002"/>
                    <measurement group_id="O5" value="0.009" spread="0.002"/>
                    <measurement group_id="O6" value="0.020" spread="0.011"/>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount Excreted Unchanged in Urine (% of Dose) [Fe(Urine)%]</title>
        <description>Summary of BMS-986251 Excretion Parameters in Urine. PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7 ; Part B : Day 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Amount Excreted Unchanged in Urine (% of Dose) [Fe(Urine)%]</title>
          <description>Summary of BMS-986251 Excretion Parameters in Urine. PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>Percentage of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0.012" spread="0.011"/>
                    <measurement group_id="O5" value="0.031" spread="0.007"/>
                    <measurement group_id="O6" value="0.033" spread="0.018"/>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance [CL(R)]</title>
        <description>Summary of BMS-986251 Excretion Parameters in Urine. PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part A: Days 1, 2, 3, 4, 5, 6, 7 ; Part B : Day 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance [CL(R)]</title>
          <description>Summary of BMS-986251 Excretion Parameters in Urine. PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0.00005" spread="0.00004"/>
                    <measurement group_id="O5" value="0.00016" spread="0.00006"/>
                    <measurement group_id="O6" value="0.00019" spread="0.00012"/>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve Over 24 Hours (One Dosing Interval) [AUC(0-24)] (Part B)</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part B : Days 1 and Day 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve Over 24 Hours (One Dosing Interval) [AUC(0-24)] (Part B)</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of AUC(0-24) Following Last Dose to AUC(0-24) Following First Dose [AR[AUC(0-24)]] (Part B)</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part B : Day 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of AUC(0-24) Following Last Dose to AUC(0-24) Following First Dose [AR[AUC(0-24)]] (Part B)</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Cmax Following Last Dose to Cmax Following First Dose [AR(Cmax)] (Part B)</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part B : Day 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Cmax Following Last Dose to Cmax Following First Dose [AR(Cmax)] (Part B)</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pre-dose Plasma Concentration (Cpre) (Part B)</title>
        <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
        <time_frame>Part B : Days 2-14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Plasma Concentration (Cpre) (Part B)</title>
          <description>PK parameters were derived from BMS-986251 concentration versus time data measured at the time points specified</description>
          <population>All participants who received at least 1 dose of BMS-986251 and had any available concentration-time data. Additionally, the evaluable PK population was defined as participants who had adequate PK profiles.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Inhibition [I(Max)]</title>
        <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
        <time_frame>Part A: Days 1, 2, 3, 5, 7, 11 ; Part B : Day 1, 2, 16, 20, 24</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Inhibition [I(Max)]</title>
          <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
          <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
          <units>Percent inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="24.0"/>
                    <measurement group_id="O2" value="36.9" spread="9.54"/>
                    <measurement group_id="O3" value="44.2" spread="8.89"/>
                    <measurement group_id="O4" value="58.2" spread="4.18"/>
                    <measurement group_id="O5" value="72.7" spread="11.3"/>
                    <measurement group_id="O6" value="73.9" spread="10.9"/>
                    <measurement group_id="O7" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Inhibition [t(Imax)]</title>
        <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
        <time_frame>Part A: Days 1, 2, 3, 5, 7, 11 ; Part B : Day 1, 2, 16, 20, 24</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Inhibition [t(Imax)]</title>
          <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
          <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="240.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="24.00"/>
                    <measurement group_id="O3" value="13.00" lower_limit="1.00" upper_limit="240.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="1.00" upper_limit="48.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="1.00" upper_limit="24.00"/>
                    <measurement group_id="O6" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Inhibition Above 50% [t(I&gt;50%)]</title>
        <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
        <time_frame>Part A: Days 1, 2, 3, 5, 7, 11 ; Part B : Day 1, 2, 16, 20, 24</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Inhibition Above 50% [t(I&gt;50%)]</title>
          <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
          <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Inhibition&gt;50% showed an intermittent pattern (above and below 50%) over time. Due to the variation over time it was not possible to calculate a reliable [t (I&gt;50%)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Inhibition&gt;50% showed an intermittent pattern (above and below 50%) over time. Due to the variation over time it was not possible to calculate a reliable [t (I&gt;50%)</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Inhibition&gt;50% showed an intermittent pattern (above and below 50%) over time. Due to the variation over time it was not possible to calculate a reliable [t (I&gt;50%)</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">Inhibition&gt;50% showed an intermittent pattern (above and below 50%) over time. Due to the variation over time it was not possible to calculate a reliable [t (I&gt;50%)</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">Inhibition&gt;50% showed an intermittent pattern (above and below 50%) over time. Due to the variation over time it was not possible to calculate a reliable [t (I&gt;50%)</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">Inhibition&gt;50% showed an intermittent pattern (above and below 50%) over time. Due to the variation over time it was not possible to calculate a reliable [t (I&gt;50%)</measurement>
                    <measurement group_id="O7" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Inhibition Above 90% [t(I&gt;90%)]</title>
        <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
        <time_frame>Part A: Days 1, 2, 3, 5, 7, 11 ; Part B : Day 1, 2, 16, 20, 24</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part A: BMS-986251 2 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O3">
            <title>Part A: BMS-986251 6 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O4">
            <title>Part A: BMS-986251 15 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O5">
            <title>Part A: BMS-986251 30 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O6">
            <title>Part A : BMS-986251 60 mg</title>
            <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O7">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O8">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Inhibition Above 90% [t(I&gt;90%)]</title>
          <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
          <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data did not allow for these calculations</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Data did not allow for these calculations</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Data did not allow for these calculations</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">Data did not allow for these calculations</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">Data did not allow for these calculations</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">Data did not allow for these calculations</measurement>
                    <measurement group_id="O7" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Inhibition [I(Pre)] (Part B)</title>
        <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
        <time_frame>Part B : Days 2, 4, 7, and 14</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Inhibition [I(Pre)] (Part B)</title>
          <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
          <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
          <units>Percent inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inhibition at Time t [I(t)] (Part B)</title>
        <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
        <time_frame>Part B : Days 16, 20, and 24</time_frame>
        <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
          <group group_id="O2">
            <title>Part B: 3 mg QD (Once Daily)</title>
            <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition at Time t [I(t)] (Part B)</title>
          <description>Summary of IL-17 Inhibition in Whole Blood Pharmacodynamic (PD) Parameters</description>
          <population>All participants who received at least 1 dose of BMS-986251 or placebo and had any available concentration-time data for the PD assessments. Additionally, the evaluable PD population was defined as participants who had adequate PD profiles.</population>
          <units>Percent inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Due to the early termination of the study, only one subject was exposed to multiple doses of BMS-986251 in Part B.Individual data not presented to maintain confidentiality</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs: Day 1 to Day 11 (Part A), Day 1 to Day 24 (Part B); SAEs: Day -21 to within 30 days of discontinuation of dosing (Part A), Day -21 to within 30 days of discontinuation of dosing (Part B) (Approximately 9 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A: Placebo</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="E2">
          <title>Part A: BMS-986251 2 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="E3">
          <title>Part A: BMS-986251 6 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="E4">
          <title>Part A: BMS-986251 15 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="E5">
          <title>Part A: BMS-986251 30 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="E6">
          <title>Part A : BMS-986251 60 mg</title>
          <description>Part A Single Ascending Dose (SAD) in Healthy Participants; single escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="E7">
          <title>Part B: Placebo</title>
          <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
        </group>
        <group group_id="E8">
          <title>Part B: 3 mg QD (Once Daily)</title>
          <description>Part B Multiple Ascending Dose (MAD) in Healthy Participants; daily escalating oral doses of BMS-986251 or placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version v21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Catheter Site Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Catheter Site Related Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Complication Associated With Device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Medical Device Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Poor Quality Sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the early termination of the study, only one participant was exposed to multiple doses of BMS-986251.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please Email</phone>
      <email>clinical.trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

